Retrospective analysis of pediatric multiple sclerosis in the Republic of Bashkortostan

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Multiple sclerosis (MS) primarily starts in the young and may develop in children. The ratio of girls to boys younger than 10–12 is 1:1, and after puberty is 3:1. During puberty, monosymptomatic exacerbations and remitting MS are more common. An increased prevalence in pediatric patients is observed.

AIM: The paper assesses clinical and epidemiological attributes of pediatric-onset MS in the Republic of Bashkortostan.

MATERIALS AND METHODS: Clinical and epidemiological attributes of pediatric MS patients were compared with typical-onset patients. Statistics were analyzed using Statistica 22.0.

RESULTS: In the Republic of Bashkortostan, 113 cases of pediatric-onset multiple sclerosis (MS) have been recorded, which is 4.2% of the total MS cases. The prevalence of pediatric MS is 2.5 cases, the incidence is 1.3 per 100,000 children. The population is predominantly urban. Prior to MS onset, all patients had suffered from acute respiratory viral infections, and the majority (94.2%) had suffered from chickenpox. Females predominate with the ratio of 2.6:1. The average progression rate of neurologic deficit is 0.2 points per year (0.1; 1.3). In cases with the onset after 18, the rate is 0.3 points per year (0.3; 2.4); p=0.761. All pediatric patients have a relapsing-remitting MS. No significant differences were found in the clinical manifestations of pediatric- and adult-onset MS ( p<0.05).

CONCLUSION: It is required to expand clinical and epidemiological studies of multiple sclerosis (MS) in the pediatric population to ensure better diagnosis and early administration of the relevant pathogenetic therapy.

Full Text

Restricted Access

About the authors

Nailya F. Akhmetgaleeva

Republican Children’s Clinical hospital

Author for correspondence.
Email: nailya_9292@list.ru
ORCID iD: 0000-0003-1409-6704
SPIN-code: 7926-0260
Russian Federation, Ufa

Oscar V. Lyutov

Bashkir State Medical University

Email: lyutov@yandex.ru
ORCID iD: 0000-0003-1393-1122
SPIN-code: 6435-3559
Russian Federation, Ufa

Klara Z. Bakhtiyarova

Bashkir State Medical University

Email: bsmu-neuro@yandex.ru
ORCID iD: 0000-0003-0982-4324
SPIN-code: 4129-2864

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Ufa

References

  1. Gusev EI, Boyko AN. Multiple sclerosis: a scientific and practical guide in two volumes. Vol. 1. Moscow: ROOI "Human Health"; 2020. (In Russ.)
  2. Valis M, Pavelek Z, Novotny M, et al. Analysis of the group of pediatric patients with relapsing-remitting multiple sclerosis: data from the Czech national registry. Front Neurol. 2022;13:851426. doi: 10.3389/fneur.2022.851426
  3. Sivertseva SA, Bykova OV, Bakhtiyarova KZ, et al. Clinical cases of multiple sclerosis in children with cerebral palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8–2):55–61. EDN: YBMCDB doi: 10.17116/jnevro201811808255
  4. Hardy D, Chitnis T, Waubant E, Banwell B. Preventing multiple sclerosis: the pediatric perspective. Front Neurol. 2022;13:802380. doi: 10.3389/fneur.2022.802380
  5. Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18(1):27. doi: 10.1186/s12883-018-1026-3
  6. El’chaninova EYu, Smagina IV. Pediatric multiple sclerosis. Neurological Journal. 2017;22(2):64–71. EDN: YUEYVL
  7. Ghezzi A, Amato MP, Makhani N, et al. Pediatric multiple sclerosis: Conventional first-line treatment and general management. Neurology. 2016;87(9 Suppl 2):S97–S102. doi: 10.1212/WNL.0000000000002823
  8. Kornbluh AB, Kahn I. Pediatric multiple sclerosis. Semin Pediatr Neurol. 2023;46:101054. doi: 10.1016/j.spen.2023.101054
  9. Ahn JJ, O'Mahony J, Moshkova M, et al. Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. Mult Scler. 2015;21(6):735–748. doi: 10.1177/1352458514551453
  10. Haki M, Al-Biati HA, Al-Tameemi, ZS, et al. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024;103(8):e37297. doi: 10.1097/MD.0000000000037297
  11. de Chalus A, Taveira M, Deiva K. Pediatric onset multiple sclerosis: Future challenge for early diagnosis and treatment. Presse Med. 2021;50(2):104069. doi: 10.1016/j.lpm.2021.104069
  12. Bakhtiyarova KZ, Lyutov OV, Talipova ID, et al. Epidemiological characteristics of multiple sclerosis in the Republic of Bashkortostan : Abstracts of the 5th Congress on Multiple Sclerosis and Other Demyelinating Diseases (Ufa, September 28–30, 2023). S.S. Korsakov Journal of Neurology and Psychiatr. 2023;123(7–2):136–180. doi: 10.17116/jnevro2023123072136
  13. Timasheva YR, Nasibullin TR, Tuktarova IA, et al. Multilocus evaluation of genetic predictors of multiple sclerosis. Gene , 2022;809:146008. doi: 10.1016/j.gene.2021.146008
  14. Utyagulova NF, Galiullin TR, Bakhtiyarova KZ, Lyutov OV. Pediatric multiple sclerosis in Bashkortostan Republic. Practical Medicine. 2020;18(5):76–78. EDN: LZLCJL doi: 10.32000/2072-1757-2020-5-76-78
  15. Goncharova ZA, Pogrebnova YuYu, Trinitatskiy YuV, Sycheva TV. Familial multiple sclerosis: literature review, own data analysis. Practical Medicine. 2020;18(5):69–75. EDN: RUDZNJ doi: 10.32000/2072-1757-2020-5-69-75
  16. Khabirov FA, Khaybullin TI, Granatov EV, et al. Multiple sclerosis in the Republic of Tatarstan: epidemiological and clinical characteristics. Practical Medicine. 2020;18(5):50–57. EDN: DVTHND doi: 10.32000/2072-1757-2020-5-50-57
  17. Boyko A, Melnikov M. Prevalence and incidence of multiple sclerosis in Russian Federation: 30 years of studies. Brain Sci. 2020;10(5):305. doi: 10.3390/brainsci10050305
  18. Hottenrott T, Dersch R, Berger B, et al. The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. Fluids Barriers CNS. 2015;12:27. doi: 10.1186/s12987-015-0024-8
  19. Boyko AN, Bykova OV, Sivertseva SA. Disease modifying therapy of multiple sclerosis in children and adolescences. Practical Medicine. 2017;1(1):28-34. EDN: YHZKML
  20. Bykova OV, Nankina IA, Drozdova IM, et al. Disease-modifying drugs in pediatric patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2–2):44–53. EDN: VQXZCR doi: 10.17116/jnevro20161162244-53
  21. Spelman T, Simoneau G, Hyde R, et al. Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: a registry-based study. Neurology. 2024;102(7):e208114. doi: 10.1212/WNL.0000000000208114
  22. Malani Shukla N, Casper TC, Ness J, et al. Demographic features and clinical course of patients with pediatric-onset multiple sclerosis on newer disease-modifying treatments. Pediatr Neurol. 2023;145:125–131. doi: 10.1016/j.pediatrneurol.2023.04.020
  23. Sharmin S, Roos I, Malpas CB, et al. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Lancet Child Adolesc Health. 2024;8(5):348–357. doi: 10.1016/S2352-4642(24)00047-6
  24. Ghezzi A. Old and new strategies in the treatment of pediatric multiple sclerosis: a personal view for a new treatment approach. Neurol Ther. 2024;13(4):949–963. doi: 10.1007/s40120-024-00633-6
  25. Nasr Z, Casper TC, Waltz M, et al. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024;87:105647. doi: 10.1016/j.msard.2024.105647

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Disabled pediatric-onset multiple sclerosis patients in the Republic of Bashkortostan (2009–2024).

Download (117KB)
Indexing metadata

Copyright (c) 2024 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.